Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer

Lung

Volumn 191, Issue 4, 2013, Pages 313-319

  Ghimire, Saurav ^a   Kyung, Eunjung ^a   Kim, Eunyoung ^b  

^a Chungnam National University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Advanced stage; Clinical trials; Non small cell lung cancer; Phase II trials; Phase III trials; Primary outcomes; Secondary outcomes

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SAFETY; TREND STUDY;

EID: 84880799379     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9479-z     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249. doi: 10.3322/caac.20006
2. Inoue K, Narukawa M, Takeuchi M (2012) Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials. Lung 190(4):355-364. doi: 10.1007/s00408-012-9379-7
3. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010):899-909. doi: 10.1136/bmj.311.7010.899
4. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21(7):1404-1411
5. Guidance for industry clinical trial endpoints for the approval of non-small cell lung cancer drugs and biologics (2011) Draft guidance. http://www.fda.gov/downloads/Drugs/./Guidances/UCM259421.pdf. Accessed 21 Dec 2012
6. Pilz LR, Manegold C, Schmid-Bindert G (2012) Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 1:26-35. doi: 10.3978/j.issn.2218-6751.2011.12.08
7. Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20(18 Suppl):42S-46S
8. Zia MI, Siu LL, Pond GR, Chen EX (2005) Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23(28):6982-6991. doi: 10.1200/jco.2005.06.679
9. Gralla RJ, Griesinger F (2007) Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol 2(Suppl 2):S51-S58. doi: 10.1097/01.JTO.0000269734.27047.3e
10. US National Institute of Health Clinical Trial Registry (2012). http://www.clinicaltrials.gov/. Accessed 21 Dec 2012
11. Mariani L, Marubini E (2000) Content and quality of currently published phase II cancer trials. J Clin Oncol 18(2):429-436
12. Dowlati A, Fu P (2008) Is response rate relevant to the phase II trial design of targeted agents? J Clin Oncol 26(8):1204-1205. doi: 10.1200/jco.2007.15.2827
13. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer. Lancet 356(9227):373-378
14. George SL (2007) Response rate as an endpoint in clinical trials. J Natl Cancer Inst 99(2):98-99. doi: 10.1093/jnci/djk024
15. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiya NH (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198(4):737-745. doi: 10.2214/ajr.11.7483
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials G (205) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132. doi: 10.1056/NEJMoa050753
17. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15(6):1873-1882. doi: 10.1158/1078-0432.ccr-08-2034
18. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512. doi: 10.1200/jco.2005.03.6723
19. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293-4300. doi: 10.1200/jco.2005.01.3441
20. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, Group TS (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134. doi: 10.1056/NEJMoa060655
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390. doi: 10.1056/NEJMoa0708857
22. Garon EB (2012) Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 77(3):475-481. doi: 10.1016/j.lungcan.2012.06.007
23. Soria JC, Massard C, Le Chevalier T (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21(12):2324-2332. doi: 10.1093/annonc/mdq204
24. Wu W, Sargent D (2010) Choice of endpoints in cancer clinical trials. In: Kelly WK, Halabi S (eds) Oncology clinical trials. Successful design, conduct, and analysis. Demos Medical Publishing, New York, pp 35-42
25. Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, Perrone F (2010) Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 67(2):127-135. doi: 10.1016/j.lungcan.2009. 10.001
26. Hunsberger S, Albert PS, Dodd L (2010) Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error. Clin Trials 7(6):634-642. doi: 10.1177/1740774510384887
27. Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J (2009) Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 15(5):386-394. doi: 10.1097/PPO.0b013e3181b9c5ec
28. Zhuang SH, Xiu L, Elsayed YA (2009) Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J 15(5):395-400. doi: 10.1097/PPO.0b013e3181be231d
29. Fleming TR, Rothmann MD, Lu HL (2009) Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27(17):2874-2880. doi: 10.1200/jco.2008.20.4107
30. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125(7):605-613
31. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M (2013) Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2,334 patients from 5 randomised trials. BMJ Open 3(3):e001802. doi: 10.1136/bmjopen-2012-001802
32. Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K (2012) Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer 79(1):20-26. doi: 10.1016/j.lungcan.2012.10.007
33. Saad ED, Adamowicz K, Katz A, Jassem J (2012) Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev 38(6):807-814. doi: 10.1016/j.ctrv.2012.02.012
34. Temel J (2007) Complexities of quality of life analysis in non-small cell lung cancer. J Support Oncol 5(1):30-31
35. Custodio A, Mendez M, Provencio M (2012) Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001
36. Gralla RJ, Thatcher N (2004) Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 46(Suppl 2):S41-S47
37. Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G, Bottomley A (2011) Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29(15):2104-2120. doi: 10.1200/jco.2010.32.3683
38. Reynolds T (2000) Eliminating publication bias: the effect of negative trial results. J Natl Cancer Inst 92(9):682
39. Lopez MF, Dupuy JF, Gonzalez CV (2012) Effectiveness of adaptive designs for phase II cancer trials. Contemp Clin Trials 33(1):223-227. doi: 10.1016/j.cct.2011.09.017